Order Article Reprints

Derakhshani A, Asadzadeh Z, Safarpour H, Leone P, Shadbad MA, Heydari A, Baradaran B, Racanelli V. Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs. Journal of Personalized Medicine. 2021; 11(8):721. https://doi.org/10.3390/jpm11080721

Derakhshani, Afshin, Zahra Asadzadeh, Hossein Safarpour, Patrizia Leone, Mahdi Abdoli Shadbad, Ali Heydari, Behzad Baradaran, and Vito Racanelli. 2021. "Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs" Journal of Personalized Medicine 11, no. 8: 721. https://doi.org/10.3390/jpm11080721

Derakhshani, A., Asadzadeh, Z., Safarpour, H., Leone, P., Shadbad, M. A., Heydari, A., Baradaran, B., & Racanelli, V. (2021). Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs. Journal of Personalized Medicine, 11(8), 721. https://doi.org/10.3390/jpm11080721